The primary aim of this randomized controlled trial is to evaluate the effect of ConquerFear-Group (CF-G), compared with a control condition (CC), on Fear of Cancer Recurrence (FCR). Secondary aims are to explore the effect of CF-G on emotion regulation and additional psychological outcomes, and to explore mediating effects of emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion. In addition, treatment expectancy, participation in other treatments after completion of the intervention of the study and demographic and clinical variables will be explored as moderators.
A randomized controlled trial testing the efficacy of ConquerFear-Group (CF-G) on breast cancer survivors with clinical levels of Fear of Cancer Recurrence (FCR), compared with a control condition (CC), will be conducted. The aims are to: 1. Evaluate the efficacy of CF-G on FCR, 2. Explore the effects on the secondary outcomes of emotion regulation, general distress, health-related QoL, survivors' unmet needs, mindfulness, metacognitions, intervention satisfaction, negative effects of intervention, and sleep. 3. Explore emotion regulation, metacognitions, working alliance, patient adherence, and group cohesion will be explored as possible mediators.\* 4. Explore treatment expectancy, participation in other treatments after completion of the CF-G or the CC and demographic and clinical variables as possible moderators. Primary hypothesis: CF-G will yield larger reductions in FCR than CC at post treatment, and the effect will be maintained through the follow-up period. Secondary hypotheses: CF-G will demonstrate a larger improvement in measures of emotion regulation than CC following the intervention period. Changes in emotion regulation during treatment will mediate the effect of CF-G on FCR.\* Changes in metacognitions during treatment will mediate the effect of CF-G on FCR.\* CF-G will yield larger reductions in general distress, health-related QoL, survivors' unmet needs than CC, and CF-G will yield larger improvements in metacognitions, mindfulness, and sleep than CC following the intervention period. \*The prerequesties for conducting for mediation analysis were not fulfilled. Consequently, these analyses were abandoned. Data can be obtained upon request.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
85
The intervention consist of one 1½-hour individual session in which a psychologist will conduct an oral psychological assessment, and five 2-hour group sessions. The key goals of the intervention are to: a) teach strategies for controlling worry and excessive threat monitoring; b) modify underlying unhelpful beliefs about worry; c) develop appropriate monitoring and screening behaviors; d) educate about follow-up care and empirically-supported behavioral change (e.g., weight loss, exercise, etc.) to improve overall survival; e) address existential changes brought about by a cancer diagnosis; f) promote goal-setting. Each session is accompanied by home-based practice of skills learned in session and home reading to consolidate skill acquisition. Four trained psychologists (MSc) will perform the therapy. The intervention will be delivered on Zoom, a secure online platform.
The control group will receive one 1½-hour individual session and participate in five 2-hour group sessions. Patients will receive guided progressive muscle relaxation training. The intervention will be delivered on Zoom, a secure online platform.
Aarhus University Hospital
Aarhus, Denmark
Fear of cancer recurrence
Changes in fear of cancer recurrence will be measured with the 42-item Fear of Cancer Recurrence Inventory at baseline, 1 week post intervention, 3- and 6-months follow-up, and session-by-session with the 9-item Fear of Cancer Recurrence Inventory-Short Form
Time frame: Baseline, 1, 2, 3, 4, 5, and 6 weeks after baseline, 1 week post intervention, 3- and 6-months follow-up
Emotion regulation
Changes in emotion regulation will be assessed with the Difficulties in Emotion Regulation Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
General distress 1
Changes in general distress will be measured with the Impact of Event Scale-Revised Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
General distress
Changes in general distress will be measured with the Depression, Anxiety, Stress Scale-21 Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Health-related quality-of-life
Changes in health-related quality-of-life will be measured with the European Organization for Research and Treatment of Cancer QLQ-C30 Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Health-related quality-of-life
Changes in health-related quality-of-life will be measured with EuroQol-5 Domain Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Survivors' unmet needs
Changes in survivors' unmet needs will be measured with the Survivors' Unmet Need Survey - 8 item Information Sub-Scale Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Fear of cancer recurrence
Changes in fear of cancer recurrence will be measured with the Concerns About Recurrence Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Metacognitions
Changes in metacognitions will be measured with the Metacognitions Questionnaire-30
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Mindfulness
Changes in mindfulness will be measured with the Five Facet Mindfulness Questionnaire
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Sleep
Changes in sleep will be measured with the Insomnia Severity Index
Time frame: Baseline, one week post intervention, 3- and 6-months follow-up
Negative effects of intervention
Negative effects of the intervention will be assessed with one question about negative effects of the intervention experienced by the participants (narrative response)
Time frame: One week post intervention, 3- and 6-months follow-up
Negative effects of intervention
Negative effects of the intervention will be measured with the Negative effects Questionnaire - hopelessness and failure subscales
Time frame: One week post intervention, 3- and 6-months follow-up
Intervention satisfaction
Intervention satisfaction will be measured with three questions regarding satisfaction with the treatment
Time frame: One week post intervention, 3- and 6-months follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.